Overview

Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State

Status:
Completed
Trial end date:
2018-12-19
Target enrollment:
Participant gender:
Summary
This single center, randomized, single dose, full replicate, crossover comparative laboratory-blinded study will be conducted in healthy male and female volunteers in order to determine the bioequivalence of two different formulations of telmisartan 80 mg tablets after oral administration under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Pharmtechnology LLC
Collaborator:
Algorithme Pharma, An Altasciences Company
Treatments:
Telmisartan